Page 41 - Test PDF v5

« Back to Contents CERVICAL CANCER

LiFE re

Literature for ENYGO

Emerging molecular-targeted therapies or early preclinical trials
in cervical cancer

Relevant articles retrieved Nov 2015 - Feb 2016

No Title Authors Journal Link to abstract
Xie FF et al. Am J Cancer Res.
1 Volasertib suppresses tumor growth and potentiates the activity of cisplatin Ji J et al. http://www.ncbi.nlm.nih.gov/
in cervical cancer. Lin MT et al. Nanoscale Res Lett. pubmed/26885445

2 Enhanced Antiproliferative Effect of Carboplatin in Cervical Cancer Cells Milosevic MF et al. Tumour Biol. http://www.ncbi.nlm.nih.gov/
Utilizing Folate-Grafted Polymeric Nanoparticles. Zhang D et al. pubmed/26608536
Pandurangan M et al.
3 Synergistic effect of fisetin combined with sorafenib in human cervical can- Shao FY et al. http://www.ncbi.nlm.nih.gov/
cer HeLa cells through activation of death receptor-5 mediated caspase-8/ Zaman MS et al. pubmed/26662956
caspase-3 and the mitochondria-dependent apoptotic pathway.
Int J Radiat Oncol Biol Phys. http://www.ncbi.nlm.nih.gov/
4 Sorafenib Increases TumorTumour Hypoxia in Cervical Cancer Patients Trea- pubmed/26547383
ted With Radiation Therapy: Results of a Phase 1 Clinical Study. Biochem Biophys Res
Commun. http://www.ncbi.nlm.nih.gov/
5 Propofol promotes cell apoptosis via inhibiting HOTAIR mediated mTOR Biol Trace Elem Res. pubmed/26523512
pathway in cervical cancer.
Oncotarget. 2016 http://www.ncbi.nlm.nih.gov/
6 Anti-Proliferative Effect of Copper Oxide Nanorods Against Human Cervical pubmed/26811107
Carcinoma Cells. Sci Rep.
http://www.ncbi.nlm.nih.gov/
7 EM23, a natural sesquiterpene lactone, targets thioredoxin reductase to Arch Toxicol. pubmed/26758418
activate JNK and cell death pathways in human cervical cancer cells.
http://www.ncbi.nlm.nih.gov/
8 Curcumin Nanoformulation for Cervical Cancer Treatment. pubmed/26837852

9 Inhibitory effect of snake venom toxin on NF-κB activity prevents human Lee HL et al. http://www.ncbi.nlm.nih.gov/
pubmed/25417048
cervical cancer cell growth via increase of death receptor 3 and 5 expression.

International Journal of Gynecological Cancer, Volume 26, Supplement #1 Page 41